Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
$13.75
$13.74
$4.41
$13.80
$477.47M0.89950,664 shsN/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
$1.95
$1.59
$1.45
$1.95
$163.47M0.565 shsN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$9.25
$9.22
$3.46
$9.28
$420.52M1.3840,890 shs178,496 shs
Lannett Company, Inc. stock logo
LCI
Lannett
$1.54
$0.64
$3.72
$7.38M0.9592,067 shs280,600 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.00%0.00%+34.48%-32.76%-21.69%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00%0.00%0.00%0.00%0.00%
Lannett Company, Inc. stock logo
LCI
Lannett
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
0.00
N/AN/AN/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.00
N/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00
N/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
$327.75M1.46N/AN/A$7.37 per share1.87
Innate Pharma SA stock logo
IPHYF
Innate Pharma
$21.77M7.51N/AN/A$0.11 per share17.73
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$42.16M9.97N/AN/A$1.75 per share5.29
Lannett Company, Inc. stock logo
LCI
Lannett
$340.58M0.00N/AN/A($23.34) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
-$466.46M-$6.88N/A76.39N/A-74.93%-16.92%-5.96%N/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
-$53.53MN/A0.00N/AN/AN/AN/A9/17/2025 (Estimated)
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/A
Lannett Company, Inc. stock logo
LCI
Lannett
-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
N/AN/AN/AN/AN/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
1.13
1.75
1.45
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/A
2.60
2.60
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.19
7.02
7.02
Lannett Company, Inc. stock logo
LCI
Lannett
N/A
2.23
1.39

Institutional Ownership

CompanyInstitutional Ownership
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
N/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
66.89%
Lannett Company, Inc. stock logo
LCI
Lannett
40.28%

Insider Ownership

CompanyInsider Ownership
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
12.73%
Innate Pharma SA stock logo
IPHYF
Innate Pharma
31.89%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
13.69%
Lannett Company, Inc. stock logo
LCI
Lannett
13.12%
CompanyEmployeesShares OutstandingFree FloatOptionable
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
44034.73 millionN/AOptionable
Innate Pharma SA stock logo
IPHYF
Innate Pharma
17983.83 million57.10 millionNot Optionable
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
6345.46 millionN/AOptionable
Lannett Company, Inc. stock logo
LCI
Lannett
81010.77 million9.35 millionOptionable

Recent News About These Companies

Completing a successful tech transfer
The pharma trends leading to higher demand for CDMOs
Insider Traders Made Easy Money on Stock Offerings
Lucky Core Industries Ltd.

Media Sentiment Over Time

Top Headlines

View All Headlines
AMAG Pharmaceuticals stock logo

AMAG Pharmaceuticals NASDAQ:AMAG

AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Innate Pharma stock logo

Innate Pharma OTCMKTS:IPHYF

$1.95 0.00 (0.00%)
As of 07/3/2025

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Kindred Biosciences stock logo

Kindred Biosciences NASDAQ:KIN

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Lannett stock logo

Lannett NYSE:LCI

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.